Respiratory Disease in the COVID-19 Era

Guest Editor:

Dr. Masaki Okamoto
Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

Deadline for manuscript submissions:
closed (31 March 2023)

Message from the Guest Editor

Coronavirus Disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused a global pandemic. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called "long COVID-19". Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or an radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing. However, limited studies about pulmonary fibrosis due to long-COVID-19 exist. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina is launching a Special Issue entitled "Pulmonary Fibrosis in the COVID-19" with the aim of gathering together accurate and up-to-date scientific information of this topic. We are pleased to invite you and your co-workers to submit your original articles.

Special Issue

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius
Medical Academy, Lithuanian
University of Health Sciences,
Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us